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Introduction
The ability of cells to resist death is a hallmark of tissue homeosta-
sis and disease, especially cancer (Hanahan and Weinberg, 2011). 
With respect to cancer, resistance to chemotherapy-induced cell 
death is a problem of paramount importance (Safa, 2016). In ad-
dition, adverse conditions in the tumor microenvironment, such as 
detachments from matrix (anoikis), result in cell death, and tumor 
cells must acquire mechanisms to resist such death to survive and 
progress to metastatic disease (Buchheit et al., 2014). Our interest 
in this area has been awakened by the discovery of a novel mode of 
programmed cell death, termed ferroptosis. Ferroptosis is defined 
as an iron-dependent form of programmed cell death, which is 
characterized by lipid reactive oxygen species (ROS) accumulation 
that damages the plasma membrane by peroxidation of polyunsat-
urated fatty acids (Yang et al., 2016; Yang and Stockwell, 2016). 
At a mechanistic level, ferroptosis is triggered by the loss of activ-
ity for the lipid repair enzyme glutathione peroxidase 4 (GPX4), 
which catalyzes the reduction of lipid and other peroxides and is a 
target of several ferroptosis inducers (Yang et al., 2014). The anti-
porter system XC−, which imports cystine into the cell in exchange 
for glutamate, also has a critical role in protecting against ferropto-
sis because cysteine, the monomeric form of cystine, is converted 
to the antioxidant glutathione, which is a substrate for GPX4 (Yang 
and Stockwell, 2016). Molecules that inhibit system XC−, such as 
erastin, trigger ferroptosis, and they have proven to be useful for 
studying this process in detail (Dixon et al., 2012).
At present, the significance of ferroptosis in the context of 
epithelial and carcinoma biology is still emerging. The findings 
that ferroptosis inducers can inhibit the growth of tumor xeno-
grafts have heightened the cancer relevance of this mode of cell 
death (Yang et al., 2014; Kim et al., 2016). Although exciting, 
these findings do not provide insight into the mechanisms used 
by cells to evade ferroptosis or whether tumor cells encounter 
conditions that trigger ferroptosis and, consequently, whether 
they must acquire mechanisms to evade this process. The study 
that reported that p53-mediated tumor suppression involves 
ferroptosis (Jiang et al., 2015) provided some indication of the 
physiological relevance of this process in cancer. Ferroptosis 
also occurs in p53 mutant cells (Jiang et al., 2015) indicating 
that mechanisms other than loss of p53 function are involved in 
promoting resistance to ferroptosis.
Given the existing literature, we were intrigued by the 
possibility that integrin signaling protects cells from ferropto-
sis. We were particularly interested in the integrin α6β4 because 
several seminal studies have revealed that this integrin can 
protect epithelial and carcinoma cells from death in adverse 
conditions (Lipscomb and Mercurio, 2005; Giancotti, 2007), 
and it has been implicated in metastasis. In this study, we un-
covered a key role for α6β4 in the evasion of ferroptosis, and we 
pursued the mechanisms involved.
Results
The integrin α6β4 promotes resistance to 
erastin-induced ferroptosis
Initially, we assessed the susceptibility of MCF-10A (immor-
talized breast epithelial cells) and SUM-159 (breast carcinoma 
Increases in lipid peroxidation can cause ferroptosis, a form of cell death triggered by inhibition of glutathione peroxi-
dase 4 (GPX4), which catalyzes the reduction of lipid peroxides and is a target of ferroptosis inducers, such as erastin. 
The α6β4 integrin protects adherent epithelial and carcinoma cells from ferroptosis induced by erastin. In addition, ex-
tracellular matrix (ECM) detachment is a physiologic trigger of ferroptosis, which is evaded by α6β4. The mechanism 
that enables α6β4 to evade ferroptosis involves its ability to protect changes in membrane lipids that are proferroptotic. 
Specifically, α6β4-mediated activation of Src and STAT3 suppresses expression of ACSL4, an enzyme that enriches 
membranes with long polyunsaturated fatty acids and is required for ferroptosis. Adherent cells lacking α6β4 require an 
inducer, such as erastin, to undergo ferroptosis because they sustain GPX4 expression, despite their increase in ACSL4. 
In contrast, ECM detachment of cells lacking α6β4 is sufficient to trigger ferroptosis because GPX4 is suppressed. This 
causal link between α6β4 and ferroptosis has implications for cancer biology and therapy.
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cells) to undergo cell death after treatment with erastin, a fer-
roptosis inducer (Dixon et al., 2012) as a function of α6β4 
expression. For that purpose, we generated a CRI SPR/Cas9 
deletion of the β4 subunit of the α6β4 heterodimer (Fig. 1 A), 
leaving the α6β1 heterodimer intact, as assessed by immuno-
blotting and flow cytometry (Fig. 1 B). We observed that MCF-
10A cells that lacked α6β4 were significantly less viable in the 
presence of erastin compared with control cells, as assessed by 
colony formation assays (Fig. 1 C). The loss of viability in α6β4- 
depleted cells in response to erastin was rescued by the addi-
tion of ferrostatin-1, a specific inhibitor of ferroptosis (Dixon 
et al., 2012), or by the addition of lipophilic antioxidant 
α-tocopherol (Fig.  1  C). Similar results were obtained with 
SUM-159 cells (Fig.  1  D). Given that ferroptosis is a form 
of programmed necrosis (Dixon et al., 2012), we used the 
lactate dehydrogenase (LDH) assay to assess cytotoxicity in 
response to erastin. Treatment of α6β4-depleted MCF-10A 
cells (Fig. 1 E) or SUM-159 cells (Fig. 1 F) with erastin sig-
nificantly increased extracellular LDH activity, which was not 
observed with control cells.
An important issue is whether the ability of α6β4 to 
evade erastin-induced ferroptosis is specific to this integrin. 
As shown in Fig. 1 B, α6β4-depleted cells expressed the α6β1 
integrin, but that integrin was not sufficient to evade ferropto-
sis under those conditions. We also targeted the α3β1 integrin 
because it is a laminin receptor expressed by epithelial and 
carcinoma cells (DiPersio et al., 1997). Expression of the α3 
subunit was diminished in both MCF-10A and SUM-159 cells 
Figure 1. The α6β4 integrin promotes evasion of ferroptosis induced by erastin. (A) The β4-integrin subunit was depleted in MCF10-A and SUM-159 
cells by CRI SPR/CAS9 using two independent guide RNAs (β4-3 and β4-4). Depletion of β4 expression was verified by immunoblotting. (B) Extracts of 
β4-depleted cells were immunoprecipitated with an α6 antibody and immunoblotted with a β1 antibody to verify that these cells express α6β1 (left blot). 
Vector control and β4-depleted cells were assessed for surface expression of the α6-integrin by flow cytometry. (C and D) Control and β4-depleted MCF10-A 
or SUM-159 cells (5 × 102) were plated in 60-mm dishes in the presence of either DMSO, 10 µM erastin, erastin and 2 µM ferrostatin-1, or erastin and 
500 µM α-tocopherol, and survival was quantified after 7 d by either DMSO extraction of crystal violet-stained cells or colony counting, respectively. (E 
and F) MCF10-A or SUM-159 vector control and β4-depleted cells were assayed for LDH after 6 h of treatment with either DMSO control or 10 µM eras-
tin. (G) shRNA-mediated depletion of the α3-integrin subunit in MCF10-A and SUM-159 cells was confirmed by qPCR after 7 d of puromycin selection. 
(H) MCF10-A and SUM-159 α3-depleted cells were plated at clonal density, and survival was quantified as in C and E. All experiments were performed 
independently three times, and a representative experiment is shown. The bars in graphs represent means ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.005.
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using shRNAs, and α3 mRNA expression was evaluated by 
quantitative PCR (qPCR; Fig. 1 G). The α3-depleted cells, in 
contrast to the β4-depleted cells, were not sensitive to erastin, 
although they did form significantly fewer colonies than con-
trol cells did (Fig. 1 H).
ECM detachment triggers ferroptosis: 
Evasion by α6β4
The ability of the integrin α6β4 to protect against erastin- 
induced ferroptosis has important implications for drug tar-
geting. Nonetheless, little is known about pathophysiological 
stimuli that trigger ferroptosis. Based on previous work in-
dicating that α6β4 can promote cell survival in stress condi-
tions (Bachelder et al., 1999; Zahir et al., 2003), we assessed 
the susceptibility of α6β4-depleted cells to ferroptosis after 
detachment from the ECM. We observed that ECM-detached 
MCF-10A and SUM-159 cells lacking α6β4, but not control 
cells, exhibited a substantial decrease in viability after 24 h 
(Fig. 2 A). Ferrostatin-1 treatment of α6β4-depleted cells re-
sulted in a partial rescue of the viability of matrix-detached 
cells (Fig.  2  A). Similar results were obtained with Hs578t 
cells, another breast cancer cell line (Fig. 2 B). Treatment with 
other ferroptosis inhibitors, including liproxstatin-1 (Fig. 2 C; 
Friedmann Angeli et al., 2014), the iron chelator deferoxam-
ine (DFO), trolox, and α-tocopherol (Dixon et al., 2012), also 
resulted in a partial rescue of cell death caused by matrix de-
tachment and loss of α6β4 (Fig. 2 D). Detachment of α6β4- 
depleted cells increased cytotoxicity significantly compared 
with control cells, as assessed by the LDH assay, and that in-
crease was prevented by ferrostatin-1 (Fig. 2 E).
We also assayed cell viability as a function of time in the 
presence of ferrostatin-1 using control and α6β4-depleted cells 
(Fig. 2 F). That analysis revealed that ferroptosis occurs rapidly 
in the absence of α6β4 (between 4 and 12 h), which is consistent 
with the LDH data on adherent cells treated with erastin (Fig. 1, 
E and F). Because anoikis has been studied primarily as a form 
of apoptosis (Meredith et al., 1993; Frisch and Francis, 1994), 
we compared the ability of carbobenzoxy-valyl-alanyl-aspar-
tyl-[O-methyl]-fluoromethylketone (Z-VAD-FMK) and ferro-
statin-1 to rescue the viability of α6β4-depleted cells after ECM 
detachment. Each of those inhibitors individually was able to 
affect a partial rescue, and the combination of both inhibitors 
rescued viability completely (Fig. 2 G).
To control for the specificity of α6β4 depletion, we engi-
neered a β4 expression construct that could not be targeted by 
CRI SPR–Cas9. Expression of that construct in α6β4-depleted 
cells protected those cells from the loss of viability caused by 
ECM detachment (Fig. 3 A). We also assessed the viability of 
the MCF10-A and SUM-159 α3-depleted cells used in Fig. 1 G 
in detached conditions and found a moderate decrease in viabil-
ity that was not rescued with ferrostatin-1 (Fig. 3 B).
We extended our analysis of ferroptosis induced by ECM 
detachment to human breast tumors. For that purpose, we used 
patient-derived xenografts (PDXs) of triple-negative breast tu-
mors. After isolation, dissociation, and lineage depletion, tumor 
cells were sorted based on the level of β4 surface expression into 
β4high and β4low populations, taking the top and bottom quartiles, 
respectively (Fig. 3 C). Those two populations were assessed 
for viability in detached conditions, either in the presence or 
absence of ferrostatin-1. Under those conditions, the β4low pop-
ulation was significantly less viable than the β4high population, 
and that loss of viability was rescued by ferrostatin-1 (Fig. 3 D).
Src, which is activated by α6β4, protects 
against ferroptosis
The signaling pathways that enable cells to evade ferroptosis 
are poorly understood. We focused on the potential role of Src, 
because several studies have documented the robust activation 
of Src by α6β4, and examined the functional consequences 
(Gagnoux-Palacios et al., 2003; Bertotti et al., 2006; Merdek et 
al., 2007; Dutta and Shaw, 2008; Yang et al., 2010; Sharma et 
al., 2012; Pavlova et al., 2013; Hoshino et al., 2015). Activation 
of Src in α6β4-depleted MCF-10A and SUM-159 cells was sig-
nificantly reduced compared with vector controls, as assessed 
by Y418 immunoblotting (Fig. 4 A), indicating that α6β4 pro-
motes Src activation in ECM detachment. To evaluate a causal 
role for Src activation in ferroptosis evasion, control cells were 
treated with the Src inhibitor PP2 and assayed for viability 24 h 
after detachment (Fig. 4 B). Strikingly, Src inhibition decreased 
cell viability significantly, and that loss of viability was rescued 
by ferrostatin-1 and other ferroptosis inhibitors (Fig. 4 B).
Next, we assessed Src activation in adherent cells in re-
sponse to erastin based on the assumption that erastin treat-
ment stresses cells and elicits a response to diminish that stress. 
Indeed, erastin treatment of control MCF-10A and SUM-159 
cells significantly increased Src activation compared with 
α6β4-depleted cells (Fig. 4 C). Moreover, the viability of de-
tached, α6β4-depleted cells was rescued by expression of an 
inducible, constitutively active Src (Fig. 4 D). These findings 
support the hypothesis that α6β4 facilitates Src activation 
in response to stress (ECM detachment or inhibition of the 
system XC− by erastin).
In pursuit of the mechanism by which Src activation 
protects against ferroptosis, we were intrigued by the recent 
studies that found the enzyme acyl-CoA synthetase long-chain 
family member 4 (ACSL4) is required for ferroptosis because 
it synthesizes polyunsaturated fatty acids that are the primary 
target of lipid peroxidation (Doll et al., 2017). We quantified 
ACSL4 mRNA expression in MCF10-A and SUM-159 con-
trol and α6β4-depleted cells in adherent and detached condi-
tions (Fig.  5 A) and found a significant elevation of ACSL4 
mRNA with the loss of α6β4 in both conditions. This eleva-
tion of ACSL4 expression was also seen at the protein level in 
α6β4-depleted cells (Fig. 5 B). Src inhibition increased ACSL4 
expression in control cells (Fig. 5 C), indicating that it has a 
causal role in regulating this key ferroptotic enzyme. More-
over, reexpression of the β4 subunit in α6β4-depleted cells 
repressed ACSL4 (Fig.  5  D), confirming that the repression 
of ACSL4 expression is specific to α6β4-mediated signaling. 
Inhibition of ACSL4 using the thiazolidinedione rosiglitazone 
(Askari et al., 2007; Doll et al., 2017) increased the viability 
of detached, α6β4-depleted cells, confirming the key role of 
ACSL4 in ferroptosis susceptibility (Fig. 5 E). In addition, ex-
pression of constitutively active Src suppressed the expression 
of ACSL4 (Fig. 5 F). These in vitro data were substantiated by 
comparing β4 and ACSL4 expression in a cohort of patients 
with breast cancer using cBioportal, where a significant inverse 
correlation was detected (Fig. 5 G).
The preceding data raise the issue of how α6β4-medi-
ated Src activation represses ACSL4 expression. We focused 
on STAT3 because it can be activated by Src (Yu et al., 1995) 
and, more specifically, by the α6β4-Src signaling axis (Guo et 
al., 2006). Moreover, STAT3 can repress, as well as activate, 
transcription (Niu et al., 2005). Using the ENC ODE database, 
we identified STAT3 binding in several regions of the ACSL4 
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promoter and coding regions of MCF10A cells (Fig. 6 A). We 
also observed that STAT3 phosphorylation was decreased in 
α6β4-depleted cells compared with control cells after erastin 
treatment (Fig. 6, B and C) and ECM detachment (Fig. 6, D and 
E). In addition, inhibition of STAT3 using 5,15-diphenylpor-
phyrin (DPP) increased ACSL4 expression (Fig. 6 F). DPP had 
no effect on cell viability during the course of that assay (un-
published data). Collectively, these data indicate that α6β4-me-
diated Src–STAT3 activation represses expression of ACSL4, 
rendering the cell unable to undergo to ferroptosis.
ECM detachment requires an up-regulation 
of GPX4 to avoid ferroptosis
One question that arises from these data is why adherent, 
α6β4-depleted cells require erastin treatment to induce ferro-
ptosis, whereas the same cells in ECM-detached conditions 
undergo ferroptosis spontaneously? As mentioned, ACSL4 is 
necessary, but not sufficient, for ferroptosis (Doll et al., 2017). 
Therefore, we sought to identify a regulator of ferroptosis that 
was altered in detached, but not adherent, conditions. We fo-
cused on GPX4 because of its central role in ferroptosis and 
Figure 2. Matrix-deprived cells are susceptible to ferroptosis in the absence of the α6β4-integrin. (A) Control and β4-depleted cells were detached for 
24 h in the presence of either DMSO or 2 µM ferrostatin-1, and the number of viable cells was quantified. (B) Control and β4-depleted Hs578t cells were 
detached for 24 h in the presence of either DMSO or 2 µM ferrostatin-1, and the number of viable cells was quantified. (C) Control and β4-depleted 
SUM-159 cells were detached for 24 h in the presence of either DMSO or 2 µM liproxstatin-1, and the number of viable cells was quantified. (D) Control 
and β4-depleted MCF-10A and SUM-159 cells were detached for 24 h in the presence of either DMSO, 100 µM DFO, 100 µM α-tocopherol, or 500 µM 
Trolox, and the number of viable cells was quantified. (E) MCF10-A or SUM-159 vector control and β4-depleted cells were assayed for LDH after 6 h of 
detachment with either DMSO or 2 µM ferrostatin-1. (F) Vector and β4-depleted cells were incubated for the times indicated with either DMSO or 2 µM 
ferrostatin-1, and viable cells were quantified. (G) Vector and β4-depleted cells were detached for 24 h in the presence of either DMSO, 2 µM ferrostatin-1, 
25 µM Z-VAD-FMK, or ferrostatin-1 and Z-VAD-FMK, and the number of viable cells was quantified. All experiments were performed independently three 
times and a representative experiment is shown. The bars in graphs represent means ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.005.
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its ability to buffer lipid peroxidation. Moreover, GPX4 is the 
only glutathione peroxidase that accepts phospholipid hydrop-
eroxides in membranes as oxidizing substrates (Thomas et al., 
1990; Roveri et al., 1994; Seiler et al., 2008). There was no sig-
nificant difference in GPX4 expression in adherent conditions 
between control and α6β4-depleted cells (Fig. 7 A). However, 
we observed that ECM detachment caused an increase in GPX4 
expression and that cells lacking α6β4 were unable to sustain 
GPX4 mRNA expression (Fig. 7 A). That inability to up-reg-
ulate GPX4 was also seen at the protein level, and expression 
levels were rescued with exogenous β4 (Fig. 7 B).
Given that GPX4 buffers lipid peroxidation (Kriska and 
Girotti, 2005), we quantified lipid peroxidation in ECM-de-
tached cells using the malondialdehyde (MDA) assay and ob-
served that is was significantly greater in α6β4-depleted cells 
than it was in control cells (Fig. 7 C). In adherent conditions, 
loss of α6β4 increases lipid peroxidation compared with vec-
tor control; however, the loss of ECM contact significantly in-
creases the burden of lipid peroxidation in those α6β4-depleted 
cells. Accordingly, glutathione peroxidase activity was elevated 
in detached, vector-controlled MCF10-A and SUM-159 cells 
compared with α6β4-depleted cells (Fig. 7 D).
To test whether the loss of GPX4 was responsible for the 
ferroptosis observed in α6β4-depleted cells upon ECM detach-
ment, we expressed exogenous GPX4 in control and α6β4-de-
pleted cells (Fig. 7 E). Exogenous GPX4 expression reduced cell 
death significantly in ECM-detached MCF10-A and SUM-159 
cells lacking α6β4, but it had no effect on the viability of control 
cells (Fig. 7 F). Importantly, α6β4-depleted cells that expressed 
exogenous GPX4 were sensitive to erastin, consistent with the 
fact that system XC−, which is the target of erastin, functions 
upstream of GPX4 (Yang and Stockwell, 2016; Fig. 7 G).
Discussion
This study advances our knowledge of ferroptosis with respect 
to physiologic processes that trigger this form of cell death and 
mechanisms used by cells to resist it. As discussed recently, 
ferroptosis occurs when a “cell is sabotaged by its own ongo-
ing normal cellular metabolic activity, such as the production 
of lipid hydroperoxides” and that it can be prevented if these 
normal activities are inhibited (Dixon, 2017). Our data sub-
stantiate that assessment and reveal that physiological (ECM 
detachment), as well as chemical (erastin), stimuli induce fer-
roptosis in epithelial and carcinoma cells. We also discovered 
a novel mechanism used by those cells to prevent such meta-
bolic disruption that involves the α6β4 integrin. The fact that 
α6β4 expression is characteristic of epithelial and carcinoma 
cells suggests that those cells have acquired mechanisms to 
mitigate metabolic stresses that can trigger ferroptosis. More-
over, the ability of α6β4 to evade ferroptosis is not shared by 
other integrins expressed by those cells, including α6β1 and 
α3β1, based on our findings.
The key mechanism that we uncovered for the evasion of 
ferroptosis by α6β4 involves it ability to activate Src in stress 
Figure 3. Evasion of ferroptosis is specific to the α6β4-integrin. (A) β4-depleted SUM-159 cells were transfected with either a control plasmid (vector) or 
a β4 expression construct in which the PAM sequences targeted by the guide RNAs were mutated. Rescue of β4 expression was confirmed by immunoblot-
ting and qPCR. Vector control cells, β4-depleted cells, vector control cells transfected with β4 containing PAM mutations, and β4-depleted cells transfected 
with β4 containing PAM mutations (β4-rescued cells) were detached for 24 h, and the number of viable cells was quantified. (B) MCF10-A and SUM-159 
α3-depleted cells were detached and compared with control cells for their viability after 24 h. (C and D) PDXs of triple-negative breast tumors were isolated, 
dissociated, and lineage-depleted, and the tumor cells were sorted based on the level of β4 surface expression into β4high (red) and β4low (blue) populations. 
Those two populations were assessed for viability in detached conditions, either in the presence or absence of ferrostatin-1. All experiments were performed 
independently three times, and a representative experiment is shown. The bars in graphs represent means ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.005.
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conditions and the consequent Src-mediated repression of 
ACSL4. ACSL4 generates a proferroptotic lipid composition 
in the plasma membrane, which is characterized by increased 
expression of long polyunsaturated ω6 fatty acids (Doll et al., 
2017), and its repression nullifies the ferroptotic response (Doll 
et al., 2017). The α6β4-Src signaling axis is well established, 
and it has been implicated in the diverse functions associated 
with this integrin (Gagnoux-Palacios et al., 2003; Bertotti et 
al., 2006; Merdek et al., 2007; Dutta and Shaw, 2008; Yang et 
al., 2010; Sharma et al., 2012; Pavlova et al., 2013; Hoshino et 
al., 2015). The ability of Src to evade ferroptosis by repressing 
ACSL4 via the activation of STAT3, however, is novel and it 
provides one of the first examples of a major signaling mech-
anism that has the ability to resist the altered metabolic ac-
tivity that can trigger this form of cell death. We demonstrate 
that α6β4-mediated Src activation contributes to ferroptosis 
resistance, but it is likely that other modes of Src activation 
result in such resistance, depending on the cellular context. Al-
though not addressed directly, it is likely that α6β4-mediated 
Src activation in ECM-detached cells is independent of ligand 
Figure 4. The integrin α6β4 activates Src to inhibit ferroptosis. (A) Vector control and β4-depleted cells were assessed for phosphorylated (Y418) Src 
by immunoblotting 3 h after ECM detachment. Relative phosphorylated Src was quantified by densitometry. (B) Vector control and β4-depleted cells were 
assessed for viability after 24 h of detachment in the presence of either DMSO, 10 µM PP2, PP2 and 2 µM ferrostatin-1, PP2 and 500 µM α-tocopherol, 
or PP2 and 2 µM liproxstatin-1. (C) Vector control and β4-depleted cells were assessed for phosphorylated (Y418) Src by immunoblotting after 3 h of incu-
bation with 10 µM erastin. Relative phosphorylated Src was quantified by densitometry. (D) SUM-159 vector control and β4-depleted cells that expressed 
a doxycycline-inducible, constitutively active Src were incubated for 24 h with 2 µg/ml doxycycline and then assessed for viability after 24 h of detach-
ment. All experiments were performed independently three times, and a representative experiment is shown. The bars in graphs represent means ± SD. 
*, P < 0.05; **, P < 0.01; ***, P < 0.005.
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(laminin), based on previous studies that addressed this issue 
(Pavlova et al., 2013).
Our finding that ECM detachment triggers ferropto-
sis is significant because little is known about physiologic or 
pathophysiologic mechanisms that are linked to this cell death 
process. Moreover, it is widely assumed that cells undergo 
apoptosis in response to ECM detachment (Meredith et al., 
1993; Frisch and Francis, 1994), a phenomenon referred to as 
anoikis (Frisch and Francis, 1994). Although the discovery of 
anoikis has been a significant contribution to the field, the rela-
tionships among ECM detachment and cell death mechanisms 
are more complex and anoikis-independent pathways are also 
involved (Buchheit et al., 2014). There is also evidence that 
ECM detachment can increase intracellular ROS and cause 
ROS-dependent cell death (Schafer et al., 2009), although the 
mechanisms involved are not well understood (Buchheit et al., 
2014). Our discovery that ECM detachment can trigger ferro-
ptosis provides one mechanism for these results. As demon-
strated here, ECM-detached cells are prone to both ferroptosis 
and apoptosis in the absence of α6β4. The apoptosis result is 
consistent with previous studies on this integrin (Bachelder et 
al., 1999; Zahir et al., 2003). Going forward, it will be import-
ant to determine the distinction between these two processes, 
particularly the point at which a decision is made by a cell to 
undergo either ferroptosis or apoptosis.
Although GPX4 is emerging as the critical gatekeeper of 
ferroptosis (Yang et al., 2014; Yang and Stockwell, 2016), bio-
logical mechanisms that regulate its expression or activity are 
poorly understood. In this direction, our findings substantiate 
the hypothesis that ferroptosis requires both GPX4 inhibition 
and ACSL4 activity. Adherent cells lacking α6β4 exhibit a sig-
nificant increase in ACSL4 expression, but they are not prone 
to ferroptosis because GPX4 expression is sustained and it im-
pedes lipid peroxidation. For that reason, these cells require an 
Figure 5. The integrin α6β4 represses ACSL4 to inhibit ferroptosis. Expression of ACSL4 was assessed by qPCR (A) and immunoblotting (B) in vector 
control and β4-depleted cells after 2 h of ECM detachment. (C) Expression of ACSL4 was quantified by qPCR in vector control MCF10-A or SUM-159 
cells under either adherent or detached conditions after 2 h of treatment with DMSO or 10 µM PP2. (D) Expression of ACSL4 was quantified in adherent 
vector control, β4-depleted, and β4-rescued cells by qPCR. (E) Vector control and β4-depleted cells were assessed for viability after 24 h of detachment 
in the presence of either DMSO or the ACSL4 inhibitor 5 µM rosiglitazone. (F) SUM-159 vector control and β4-depleted adherent cells that expressed a 
doxycycline-inducible, constitutively active Src were incubated for 24 h with 2 µg/ml doxycycline, and the expression of ACSL4 was quantified by qPCR. 
(G) Expression of ITGB4 and ACSL4 was correlated using a published gene expression database (cBioportal) comprising 70 human breast tumors. The 
correlation coefficient (r) was calculated using Pearson’s correlation. Experiments were performed independently three times, and a representative experi-
ment is shown. The bars in graphs represent means ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.005.
 o
n
 January 10, 2018
jcb.rupress.org
D
ow
nloaded from
 
JCB • Volume 216 • NumBer 12 • 20174294
exogenous inhibitor of GPX4, such as erastin, to undergo fer-
roptosis. In contrast, ECM detachment is sufficient to trigger 
ferroptosis in the absence of α6β4 because lipid peroxidation 
increases as a result of ACSL4 induction and diminished GPX4 
expression. Our data indicate that α6β4 contributes to sustain-
ing GPX4 expression in ECM-detached cells, but the mecha-
nism appears to be distinct from α6β4-mediated repression of 
ACSL4 by Src because Src inhibition does not affect GPX4 
expression (unpublished data).
The findings we present have potential implications for 
breast and other cancers. Although much is known about the 
mechanisms by which α6β4 contributes to epithelial biology 
and breast cancer, a cohesive mechanism has not emerged, 
and the possibility that this integrin protects tumor cells from 
excessive lipid peroxidation has not been considered. This 
mechanism is likely to be important for metastasis because 
this process involves detachment from ECM or the presence 
of the “foreign” ECM in a distant organ (Cheung and Ewald, 
2016). Moreover, we detected a significant inverse correlation 
between α6β4 and ASCL4 in a large cohort of patients with 
breast cancer, and we demonstrated that the β4low population 
isolated from PDXs of human breast cancer is much more 
susceptible to ferroptosis induced by ECM detachment than 
is the β4high population. This latter observation is of partic-
ular interest because some chemotherapeutic drugs, as well 
as more novel therapies, such as the use of nanoparticles 
to deliver tumor-targeting peptides, function by inducing 
ferroptosis (Yang et al., 2014; Kim et al., 2016). Our data 
suggest that tumor cells with high α6β4 expression could be 
resistant to such therapies.
Materials and methods
Cell lines and reagents
MCF10-A cells were obtained from the Barbara Ann Karmanos Cancer 
Institute, and SUM-159 cells were provided by S. Ethier (Medical Col-
lege of South Carolina, Charleston, SC). Hs578T cells were provided 
by D. Kim (University of Massachusetts Medical School, Worcester, 
MA). The pCMV-β4 plasmid was provided by L. Shaw (University of 
Massachusetts Medical School, Worcester, MA). A Tet-CA-Src-GFP 
construct was purchased from Addgene (plasmid 83469). All cells were 
checked quarterly for mycoplasma.
The following antibodies were used: GPX4 (Abcam), actin 
(Sigma-Aldrich), integrin β4 (505 [Rabinovitz et al., 1999] and 439-9b 
[Abcam]), α6 (GoH3; MilliporeSigma), and integrin β1 (BD), phos-
pho-Src Y418 (R&D Systems), total Src (Santa Cruz Biotechnology, 
Inc.), ACSL4 (Santa Cruz Biotechnology, Inc.), phospho-STAT3 Y705 
(Cell Signaling Technology), and total STAT3 (Cell Signaling Tech-
nology). Other reagents used were: Z-VAD-FMK (SelleckChem), 
erastin (Sigma-Aldrich), ferrostatin-1 (Sigma-Aldrich), liproxstatin-1 
(Sigma-Aldrich), DFO mesylate salt (Sigma-Aldrich), α-tocopherol 
(Sigma-Aldrich), trolox (Sigma-Aldrich), DPP (Sigma-Aldrich), and 
rosiglitazone (Tocris Bioscience).
Figure 6. STAT3 represses transcription of ACSL4 downstream of the integrin α6β4. (A) Analysis of MCF10-A cells using the ENC ODE database showed 
binding of STAT3 to the promoter region. The phosphorylation of STAT3 was assessed by immunoblotting in vector control and β4-depleted MCF-10A cells 
after 3 h of detachment (B) or after incubation with erastin (D) and was also quantified by densitometry (C and E). (F) Expression of ACSL4 was quantified 
by qPCR in vector control MCF10-A and SUM-159 adherent cells after 2 h of incubation with the STAT3 inhibitor DPP. Experiments were performed inde-
pendently three times, and a representative experiment is shown. The bars in graphs represent means ± SD. **, P < 0.01; ***, P < 0.005.
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RNA interference
Lentiviruses containing ITGA3 shRNAs (clone ID TRCN0000057713 
or TRCN0000057714; GE Healthcare) or a GFP control (RHS4459) 
were generated, titrated according to the manufacturer’s instructions, 
and used to transiently infect MCF10-A and SUM-159 vector control 
and β4-depleted cells, following standard protocols.
PDX tumors
PDX models of triple-negative breast cancer were obtained from the 
Dana-Farber Cancer Institute and propagated in NSG mice. Tumors 
were harvested and digested using collagenase at 37°C. Once digested, 
the cells were filtered using a cell strainer (40 µm), washed twice with 
PBS, and plated in DMEM/F12 (containing 10% FBS). The next day, 
cells were stained using a β4 antibody for 1 h and analyzed by flow 
cytometry. The highest and lowest quartiles of cells expressing β4 were 
collected and plated immediately for experimentation.
Colony formation assay
MCF10-A and SUM-159 vector control or β4-depleted cells (5 × 102) 
were plated on 60-mm dishes. 24 h after plating, cells were incubated in 
medium containing erastin (10 µM), erastin and ferrostatin-1 (2 µM), or 
DMSO control. Media were changed daily with continued exposure. 10 
d after the first treatment, plates were washed in PBS, fixed in 4% para-
formaldehyde, and stained in crystal violet. Plates were washed clean 
of excess dye and colonies >50 cells were counted. For some experi-
ments, the crystal violet–stained cells were solubilized with DMSO, 
and absorbance was read at 590 nm.
Matrix-detachment assays
24-well plates were coated with poly 2-hydroxyethyl methacrylate 
(polyHEMA; 30 mg/ml; Sigma-Aldrich) and dried overnight. Tryp-
sinized cells were plated (2.5 × 104 per well) in serum-free medium 
with the reagents indicated in the figure legends for the times noted. 
Cells were counted with a hemocytometer using trypan blue exclusion. 
Total cell number was calculated by multiplying the mean of cells per 
square by the dilution factor and chamber volume.
Biochemical experiments
For immunoblotting, cells were extracted using radioimmunoprecipita-
tion assay buffer containing protease inhibitors (Boston BioProducts). 
Extracts were separated by SDS-PAGE and immunoblotted using the 
antibodies specified in the figure legends. Immunoprecipitation was 
Figure 7. Matrix-deprived cells exhibit increased lipid peroxidation and an inability to sustain GPX4 expression in the absence of the α6β4-integrin. 
(A) GPX4 mRNA expression was quantified by qPCR in control and β4-depleted MCF-10A and SUM-159 cells under adherent or 2-h matrix-deprived 
conditions. (B) Expression of GPX4 was assessed by immunoblotting in vector control, β4-depleted, and β4-rescued cells after 2 h of detachment. Relative 
densitometry values are shown. (C) Lipid peroxidation was quantified using the MDA assay in control and β4-depleted, MCF-10A and SUM-159 cells 
under adherent or 4-h matrix-deprived conditions. (D) GPX enzyme activity was assayed in control and β4-depleted, MCF-10A and SUM-159 cells under 
adherent or 4-h matrix-deprived conditions. (E) Control and β4-depleted SUM-159 cells were transfected with either a vector control or a GPX4 expression 
vector. GPX4 mRNA expression was quantified by qPCR. (F) Control and β4-depleted MCF10-A and SUM-159 cells that had been transfected with either 
a vector control or a GPX4 expression vector were detached for 24 h, and the number of viable cells was quantified. (G) Control and β4-depleted cells 
that had been transfected with either a vector control or a GPX4 expression vector were detached for 24 h with in the presence of either DMSO or 10 µM 
erastin, and the number of viable cells was quantified. Experiments were performed independently three times and a representative experiment is shown. 
The bars in graphs represent means ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.005.
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performed on precleared lysates by incubation with the primary anti-
body and, subsequently, protein G sepharose beads (Sigma-Aldrich). 
Immune complexes were dissociated, and proteins were separated by 
SDS-PAGE and immunoblotted as described in the figure legends. For 
qPCR, RNA was isolated from cells with NucleoSpin Gel and the PCR 
Clean-Up kit (Macherey-Nagel), and cDNAs were produced using the 
All-In-One cDNA Synthesis SuperMix (BioScript Solutions). qPCR 
was performed using a SYBR Green master mix (biotool.com). Se-
quences for primers used are provided in Table S1. The two-tailed Stu-
dent t test was used to assess statistical significance.
To assess cytotoxicity, the LDH assay (Thermo Fisher Scien-
tific) was used, according to the manufacturer’s specifications. In brief, 
5,000 cells were cultured in 96-well adherent or polyHEMA-coated 
plates in serum-free media for 4 h in DMSO, erastin (10 µM), or fer-
rostatin-1 (2 µM), as indicated. Medium from each well was reacted to 
form red formazan. Absorbance was read at 490 and 680 nm, and the 
LDH per well was calculated.
To assay lipid peroxidation, the MDA lipid peroxidation mi-
croplate assay (Sigma-Aldrich) was used according to manufactur-
er’s specifications. In brief, cells (106) were cultured in serum-free 
medium on polyHEMA-coated plates for 4  h.  Cells were collected, 
lysed, and reacted with thiobarbituric acid. Fluorescence was read at 
532 (excitation) and 590 (emission). Lipid peroxidation levels were 
normalized to protein concentration. Glutathione peroxidase activity 
assay (BioVision) was performed according to the manufacturer’s 
specifications. In brief, cells (106) were trypsinized and cultured in 
serum-free medium on polyHEMA-coated plates for 4 h. Cells were 
lysed and challenged with cumene hydroperoxide to assess the ac-
tivity of glutathione peroxides. Plates were read at 340 nm 5 min 
after challenge. Glutathione peroxidase activity was normalized 
to protein concentration.
Molecular biology experiments
For CRI SPR-mediated deletion of the β4 integrin subunit, guide 
RNAs targeting exon 1 of the β4 sequence were selected using two 
websites, CRI SPR Design (http ://crispr .mit .edu) and CRI SPRdirect 
(https ://crispr .dbcls .jp). Four guide RNAs were tested, and the 
two most efficient knockouts were selected and used to control 
for potential off-target effects. Cells were subcloned by FACS and 
screened for loss of protein expression by immunoblot. To rescue 
the β4 deletion, the protospacer-adjacent motif (PAM) sequences 
targeted by the guide RNAs were mutated using the New England 
Biolabs, Inc., Q5 site-directed mutagenesis kit in pcDNA3.1-Myc-β4 
(16039; Addgene). Mutagenesis primers were designed using the 
New England BioLabs, Inc., BaseChanger tool. Silent mutations 
were used to prevent changes in the amino acid sequence (Table S1). 
To express constitutively active Src, MCF10-A and SUM-159 vector 
control or β4-depleted cells were incubated with lentiviral-packaged 
Tet-CA-Src-GFP for 24  h before selection with 2 µg/ml puromycin 
for 7 d. Src expression was induced by 24-h incubation with 2 µg/ml 
doxycycline. To express GPX4, a plasmid construct for GPX4 was 
purchased from OriGene (RC208065). Cells were transfected with 
10 µg DNA using Lipofectamine 2000 (Thermo Fisher Scientific) 
and incubated for 48 h before use.
ENC ODE database analysis
The signal of the STAT3 chromatin immunoprecipitation sequencing on 
the human MCF10A cell line (a stably expressed Er–Src fusion protein 
treated with 0.01% ethanol) was downloaded from the ENC ODE 
project (https ://www .encodeproject .org /experiments /ENC SR000DOZ 
/; National Human Genome Research Institute). The track was plotted 
with the Bioconductor trackViewer (version 1.12.0) package.
Statistical analysis
The bars in graphs represent means ± SD. All experiments were re-
peated at least three times. The p-value was calculated using Student’s 
t test and a p-value <0.05 was considered significant.
Online supplemental material
Table S1 lists the primers used for qPCR and mutagenesis analyses.
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Table S1. List of primers used for qPCR and mutagenesis
Primer Forward (5′–3′) Reverse (5′–3′)
18s AAC CCG TTG AAC CCC ATT CCA TCC AAT CGG TAG TAG CG
GPX4 GAG GCA AGA CCG AAG TAA ACT AC CCG AAC TGG TTA CAC GGG AA
ACSL4 CAT CCC TGG AGC AGA TAC TCT TCA CTT AGG ATT TCC CTG GTCC
ITGB4 CTC CAC CGA GTC AGC CTTC CGG GTA GTC CTG TGT CCT GTA
ITGA3 TCA ACC TGG ATA CCC GAT TCC GCT CTG TCT GCC GAT GGAG
sg-3 β4 mutation TTC TCC AAC TTC ATG TCC GATG GTC CAT GAG GAT GTA CAG
sg-4 β4 mutation AGC CAG CTC ATC AGC GAC TAC CAG GAC CCG AGC TGG ATG
